ENTX Earnings & Financial Statements
Entera Bio Ltd.
$2.77
+$0.27(+10.80%)
48
Overall
75
Value
30
Tech
39
Quality
Market Cap
$434.81M
Volume
1.45M
52W Range
$0.91 - $4.20
Target Price
$9.67
ENTX earnings and financial statements: Entera Bio Ltd.'s income statement, balance sheet and cash flow statement, annual and quarterly.
ENTX Annual Financial Statements
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | $42.0K | $181.0K | - | $134.0K | $571.0K |
| Cost of revenue | $42.0K | $172.0K | - | $101.0K | $373.0K |
| Operating income | -$11.53M | -$9.59M | -$8.89M | -$13.02M | -$12.22M |
| EBITDA | -$11.41M | -$9.48M | -$8.80M | -$12.87M | -$12.16M |
| Net income | -$11.44M | -$9.54M | -$8.89M | -$13.07M | -$12.19M |
| EPS (diluted) | $-0.25 | $-0.25 | $-0.31 | $0.45 | $0.47 |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total assets | $15.99M | $9.39M | $11.77M | $13.13M | $25.99M |
| Total liabilities | $2.89M | $1.31M | $1.38M | $1.37M | $3.42M |
| Shareholders’ equity | $13.10M | $8.08M | $10.39M | $11.75M | $22.57M |
| Cash and equivalents | $7.11M | $8.66M | $11.02M | $12.31M | $24.89M |
| Long-term debt | $260.0K | $102.0K | $256.0K | - | $123.0K |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating cash flow | -$7.37M | -$6.82M | -$7.31M | -$12.50M | -$9.06M |
| Capital expenditure | -$107.0K | -$3.0K | -$17.0K | -$47.0K | -$17.0K |
| Free cash flow | -$7.48M | -$6.82M | -$7.33M | -$12.55M | -$9.08M |
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | ENTX | $2.77 | +10.8% | 1.45M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |